Systemic chemotherapy for urothelial transitional cell carcinoma: An overview of toxicity

S. L. Moulder, B. J. Roth

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Chemotherapy for urothelial transitional cell carcinoma improves disease-related symptoms and overall survival. Unfortunately, many commonly used cytotoxic regimens affect normal as well as malignant tissue, resulting in toxicities that may require prompt medical diagnosis and management. This article reviews the reported toxicities of both single agent and combination chemotherapy regimens used to treat metastatic transitional cell carcinoma.

Original languageEnglish
Pages (from-to)194-201
Number of pages8
JournalSeminars in Urologic Oncology
Volume19
Issue number3
StatePublished - Sep 15 2001

Keywords

  • Chemotherapy
  • Toxicity
  • Urothelial carcinoma

Fingerprint

Dive into the research topics of 'Systemic chemotherapy for urothelial transitional cell carcinoma: An overview of toxicity'. Together they form a unique fingerprint.

Cite this